Caris Life Sciences (CAI) Income towards Parent Company (2024 - 2026)

Caris Life Sciences has reported Income towards Parent Company for 3 years, with the latest figure at -$637000.0 in Q2 2026.

• On a quarterly basis, Income towards Parent Company rose 99.11% year-over-year to -$637000.0 in Q2 2026; TTM through Jun 2026 was $105.1 million, a 137.68% increase from a year earlier, with the FY2025 full-year figure at -$68.1 million, up 75.85% from the prior year.
• Income towards Parent Company was -$637000.0 for Q2 2026 at Caris Life Sciences, down from -$510000.0 in the prior quarter.
• The five-year high for Income towards Parent Company was $82.0 million in Q4 2025, with the low at -$102.6 million in Q1 2025.
• Average Income towards Parent Company over 3 years is -$26.7 million, with a median of -$36.9 million recorded in 2024.
• The largest YoY upside for Income towards Parent Company was 321.82% in 2025 against a maximum downside of 8.47% in 2025.
• Over 3 years, Income towards Parent Company stood at -$36.9 million in 2024, then jumped by 321.82% to $82.0 million in 2025, then plunged by 100.78% to -$637000.0 in 2026.
• The last three Income towards Parent Company figures came in at -$637000.0 (Q2 2026), -$510000.0 (Q1 2026), and $82.0 million (Q4 2025), per Business Quant data.